Mike Ryskin's questions to Neogenomics Inc (NEO) leadership • Q1 2025
Question
Speaking on behalf of Mike Ryskin from BofA Securities, an analyst asked about how NeoGenomics is thinking about the evolution of the competitive landscape in the Minimal Residual Disease (MRD) market as it matures.
Answer
CEO Anthony Zook stated that the MRD market remains very attractive with low penetration, especially in the community setting, presenting a significant opportunity for NeoGenomics. CIO Andrew Lukowiak added that the market is in the 'early innings,' particularly regarding ultra-sensitive applications. He emphasized that NeoGenomics has an 'intellectual advantage' with in-house ctDNA pioneers, positioning the company to align with the market's evolution towards higher sensitivity over the next several years.